IGC Pharma Inc（IGC）财务数据IGCIGC Pharma Inc

IGC Pharma Inc (IGC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Tolling/White labeling service, accounting for 96.6% of total sales, equivalent to $256.00K. Another important revenue stream is Wellness and Lifestyle. Understanding this composition is critical for investors evaluating how IGC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, IGC Pharma Inc maintains a gross margin of 18.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -588.72%, while the net margin is -623.78%. These profitability ratios, combined with a Return on Equity (ROE) of -111.15%, provide a clear picture of how effectively IGC converts its operational activities into shareholder value.

In the context of the broader market, IGC competes directly with industry leaders such as BSEM and QNTM. With a market capitalization of $22.93M, it holds a leading position in the sector. When comparing efficiency, IGC's gross margin of 18.60% stands against BSEM's 52.55% and QNTM's N/A. Such benchmarking helps identify whether IGC Pharma Inc is trading at a premium or discount relative to its financial performance.

IGC Pharma's total revenue for Q1 2026 was $328,000, which is a slight decline from the previous year, and the company has been consistently reporting net losses, with the latest net income at -$2,402,000. The gross margin is relatively low at 18.60%, indicating challenges in profitability.